Table 2.
Oral Cavity HPV-associated | Oral Cavity HPV - | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Male | Female | Male | Female | |||||||
Count | % | Count | % | p-value | Count | % | Count | % | p-value | |
Mean age (years) | 58,85 | 59,72 | < 0.001 | 61,35 | 63,95 | < 0.001 | ||||
Ethnicity | 0.502 | 0.512 | ||||||||
White | 804 | 91.6% | 296 | 88.9% | 4093 | 87.7% | 2777 | 88.7% | ||
Black | 44 | 5.0% | 25 | 7.5% | 371 | 7.9% | 218 | 7.0% | ||
American Indian/Eskimo | 2 | 0.2% | 1 | 0.3% | 15 | 0.3% | 7 | 0.2% | ||
Asian/Pacific Islander | 20 | 2.3% | 9 | 2.7% | 151 | 3.2% | 103 | 3.3% | ||
Other | 8 | 0.9% | 2 | 0.6% | 39 | 0.8% | 26 | 0.8% | ||
Charlson/Deyo Score | 0.11 | 0.92 | ||||||||
0 | 689 | 77.9% | 259 | 77.1% | 3607 | 76.7% | 2434 | 77.0% | ||
1 | 165 | 18.7% | 57 | 17.0% | 837 | 17.8% | 552 | 17.5% | ||
2 | 30 | 3.4% | 20 | 6.0% | 256 | 5.4% | 174 | 5.5% | ||
AJCC Clinical Staging | ||||||||||
T Staging | 0.005 | < 0.001 | ||||||||
T0 | 4 | 0.5% | 0 | 0.0% | 8 | 0.2% | 5 | 0.2% | ||
T1 | 251 | 29.3% | 129 | 40.1% | 1579 | 34.6% | 1292 | 42.3% | ||
T2 | 277 | 32.4% | 101 | 31.4% | 1409 | 30.8% | 914 | 29.9% | ||
T3 | 96 | 11.2% | 32 | 9.9% | 506 | 11.1% | 271 | 8.9% | ||
T4 | 216 | 25.2% | 56 | 17.4% | 1039 | 22.7% | 551 | 18.1% | ||
TX | 12 | 1.4% | 4 | 1.2% | 29 | 0.6% | 19 | 0.6% | ||
N Staging | 0.003 | < 0.001 | ||||||||
N0 | 420 | 47.5% | 198 | 59.5% | 3001 | 64.0% | 2226 | 70.7% | ||
N1 | 130 | 14.7% | 46 | 13.8% | 552 | 11.8% | 332 | 10.5% | ||
N2 | 313 | 35.4% | 86 | 25.8% | 1038 | 22.2% | 551 | 17.5% | ||
N3 | 15 | 1.7% | 2 | 0.6% | 57 | 1.2% | 14 | 0.4% | ||
NX | 6 | 0.7% | 1 | 0.3% | 38 | 0.8% | 27 | 0.9% | ||
M Staging | 0.939 | 0.004 | ||||||||
M0 | 833 | 97.9% | 313 | 97.8% | 4339 | 97.7% | 2959 | 98.6% | ||
M1 | 18 | 2.1% | 7 | 2.2% | 102 | 2.3% | 41 | 1.4% | ||
Insurance Status | 0.09 | < 0.001 | ||||||||
Not Insured | 51 | 5.8% | 23 | 6.9% | 236 | 5.1% | 132 | 4.2% | ||
Private Insurance/Managed Care | 420 | 48.1% | 145 | 43.5% | 1935 | 41.9% | 1197 | 38.5% | ||
Medicaid | 90 | 10.3% | 30 | 9.0% | 515 | 11.1% | 260 | 8.4% | ||
Medicare | 286 | 32.8% | 131 | 39.3% | 1850 | 40.0% | 1480 | 47.6% | ||
Other Government | 26 | 3.0% | 4 | 1.2% | 85 | 1.8% | 38 | 1.2% | ||
Median Income Quartiles 2008–2012 | 0.22 | 0.010 | ||||||||
< $38,000 | 137 | 15.6% | 47 | 14.0% | 843 | 18.0% | 512 | 16.3% | ||
$38,000–$47,999 | 206 | 23.4% | 93 | 27.8% | 1171 | 25.0% | 725 | 23.0% | ||
$48,000–$62,999 | 264 | 30.0% | 85 | 25.4% | 1250 | 26.7% | 863 | 27.4% | ||
$63,000 + | 272 | 30.9% | 110 | 32.8% | 1426 | 30.4% | 1046 | 33.2% | ||
Urban/Rural 2013 | 0.510 | 0.072 | ||||||||
Metro | 741 | 85.2% | 287 | 87.8% | 3799 | 82.8% | 2579 | 83.9% | ||
Urban | 114 | 13.1% | 35 | 10.7% | 708 | 15.4% | 461 | 15.0% | ||
Rural | 15 | 1.7% | 5 | 1.5% | 81 | 1.8% | 35 | 1.1% | ||
Facility Type | 0.507 | 0.967 | ||||||||
Community Cancer Program | 64 | 7.6% | 20 | 6.6% | 274 | 6.1% | 188 | 6.3% | ||
Comprehensive Community Cancer Program | 239 | 28.3% | 75 | 24.8% | 1226 | 27.3% | 823 | 27.6% | ||
Academic/Research Program | 466 | 55.2% | 176 | 58.1% | 2487 | 55.3% | 1643 | 55.0% | ||
Integrated Network Cancer Program | 75 | 8.9% | 32 | 10.6% | 507 | 11.3% | 331 | 11.1% | ||
Other specified types of cancer programs | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | ||
Facility Location | 0.990 | 0.026 | ||||||||
East | 178 | 21.1% | 64 | 21.1% | 995 | 22.1% | 662 | 22.2% | ||
South | 278 | 32.9% | 98 | 32.3% | 1660 | 36.9% | 1014 | 34.0% | ||
Midwest | 240 | 28.4% | 87 | 28.7% | 1149 | 25.6% | 793 | 26.6% | ||
West | 148 | 17.5% | 54 | 17.8% | 690 | 15.4% | 516 | 17.3% | ||
Treatment Group | < 0.001 | < 0.001 | ||||||||
No treatment | 29 | 3.3% | 11 | 3.3% | 163 | 3.5% | 120 | 3.8% | ||
Radiation only | 56 | 6.3% | 26 | 7.7% | 282 | 6.0% | 217 | 6.9% | ||
Radiation and Chemo | 269 | 30.4% | 62 | 18.5% | 717 | 15.3% | 356 | 11.3% | ||
Surgery and Radiation | 100 | 11.3% | 37 | 11.0% | 573 | 12.2% | 396 | 12.5% | ||
Surgery, Chemotherapy and Radiation | 146 | 16.5% | 55 | 16.4% | 806 | 17.1% | 408 | 12.9% | ||
Surgery only | 264 | 29.9% | 139 | 41.4% | 2072 | 44.1% | 1620 | 51.3% | ||
Chemotherapy Only | 20 | 2.3% | 6 | 1.8% | 87 | 1.9% | 43 | 1.4% |